BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Phyton Biotech, Inc. Acquires Novel Glyco-Engineering Technology, Adds Enhanced Capacity to Manufacture Therapeutic Proteins


5/3/2007 9:59:18 AM

EAST WINDSOR, N.J., May 2 /PRNewswire/ --- Magnus Precht, President of Phyton Biotech, Inc., has announced the acquisition from The Dow Chemical Company of a novel, proprietary technology and intellectual property platform for the engineering of glycosylation in pharmaceutical protein products.

This acquisition will be enhanced through a research collaboration with the Dutch research institute Plant Research International (PRI), part of Wageningen University & Research Centre and one of the innovators of the technology platform.

The announcement coincides with another milestone, the installation of a second 75,000 liter bioreactor at Phyton's German cell fermentation facility.

"Our acquisition and collaboration should be viewed vis-a-vis recent developments in the glyco-engineering field, such as Merck's acquisition of GlycoFi and Roche's acquisition of Glycart," said Mr. Precht.

Dr. Laurence Korn, the co-founder and former CEO and Chairperson of PDL (a leader in humanized antibodies) and an industry leader, stressed that this technology complements the unique new protein expression platform that Phyton is developing.

"The glyco-engineering capability Phyton has acquired could allow the company to realize the full potential of its plant cell fermentation expression system," said Dr. Korn, adding that Phyton plans to apply the technology to humanizing glycosylation in monoclonal antibodies, a multi-billion dollar market.

The glyco-engineering technology has the potential to diminish the clinical effects of immunogenicity, optimize drug potency and increase drug half life. For patients, a longer half life can mean less frequent injections.

Phyton is already a leader in plant cell fermentation technology, producing paclitaxel for Bristol-Myers Squibb's TAXOL(R) oncology product.

Phyton Biotech, Inc., is based in East Windsor, N.J. Phyton's proprietary plant cell culture technology platform is used to develop and manufacture products with applications in the pharmaceutical and biotech industries. Its German subsidiary, Phyton Biotech GmbH, operates the world's largest commercial cGMP manufacturing facility for plant cell fermentation. Visit http://www.phytonbiotech.com.

* Taxol is a registered trademark of Bristol-Myers Squibb Company.

Phyton Biotech, Inc.

CONTACT: Magnus Precht of Phyton Biotech, Inc., +1-609-426-2520,magnus.precht@phytonbiotech.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->